CD19 and non-Hodgkin lymphoma: This expectation was met in 2011 when SB entered the clinical stage in the first in-human application of a transposon system worldwide to generate CD19-specific CAR-T cells to treat the minimal residual disease of patients with advanced non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplantation (HSCT) [147].